Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000144304 | SCV000964233 | pathogenic | Angelman syndrome | 2018-10-06 | criteria provided, single submitter | clinical testing | This variant is not present in population databases (ExAC no frequency). For these reasons, this variant has been classified as Pathogenic. This variant disrupts the C-terminus of the UBE3A protein. Other variants that disrupt this region (p.Lys836Argfs*4, p.Glu837Argfs*4, p.Lys836Asnfs*7, p.Leu835_Lys836del) have been observed in affected individuals (PMID: 9887341, 11748306, 26993267, 24796722). This suggests that this may be a clinically significant region of the protein. This variant has been observed in individuals affected with Angelman syndrome (PMID: 25212744, Invitae). ClinVar contains an entry for this variant (Variation ID: 155981). This sequence change results in a premature translational stop signal in the UBE3A gene (p.Ser830*). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 23 amino acids of the UBE3A protein. |
Baylor Genetics | RCV000144304 | SCV000172055 | pathogenic | Angelman syndrome | 2014-02-14 | no assertion criteria provided | clinical testing |